Testing for
            <i>Helicobacter pylori</i>
            in an era of antimicrobial resistance

Schuetz, Audrey N.; Theel, Elitza S.; Cole, Nicolynn C.; Rothstein, Tanner E.; Gordy, Garrett G.; Patel, Robin

doi:10.1128/jcm.00732-23

Cited by 4 publications

(1 citation statement)

References 61 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the near future, a shared approach, with concentration on clinical cases in a few expert centers, will be of paramount importance to ensure quality in H. pylori eradication, as already confirmed by evidence of similar experiences in other fields [37]. Furthermore, it is appropriate that clinical trials for H. pylori treatment will be supported by resistance information; this approach will be pivotal in order to reach, whenever possible, a basis for the formulation of a tailored therapy taking into account individual antimicrobial resistance profiles [38][39][40][41][42][43].…”

Section: Discussionmentioning

confidence: 92%

Concomitant and Bismuth Quadruple Therapy for Helicobacter pylori Eradication in Southern Italy: Preliminary Data from a Randomized Clinical Trial

Losurdo,

Borraccino,

Aloisio

et al. 2024

Antibiotics

View full text Add to dashboard Cite

Concomitant therapy (CT) and bismuth quadruple therapy (BQT) are recommended in geographical areas with high clarithromycin resistance for Helicobacter pylori (H. pylori) eradication. We compared CT and BQT as the first lines of treatment in a randomized controlled trial. Consecutive patients with H. pylori diagnosed by concordance of both a urea breath test and histology were recruited. For BQT, patients received 3 PyleraTM capsules q.i.d.; for CT, 1000 mg of amoxicillin b.i.d, 500 mg of clarithromycin b.i.d and 500 mg of metronidazole b.i.d. As a proton pump inhibitor, 40 mg of pantoprazole b.i.d was administered. Both regimens lasted 10 days. In total, 46 patients received CT and 38 BQT. Both groups were comparable for age (p = 0.27) and sex (p = 0.36). We did not record any drop outs; therefore, the intention to treat and per protocol rates coincided. The most common symptoms were heartburn and post-prandial fullness, which were equally present in both groups. The success rate was 95.6% for CT and 100% for BQT (p = 0.56). Side effects were recorded in 23.9% and 31.6% of patients in the CT and BQT arms, respectively (p = 0.47). The most common ones were abdominal pain (8) and diarrhea (6). In conclusion, CT and BQT are equally effective in our area with high clarithromycin resistance, southern Italy, and showed comparable safety.

show abstract